Wall Street Zen Upgrades Hologic (NASDAQ:HOLX) to Buy

Hologic (NASDAQ:HOLX) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Friday.

A number of other equities analysts have also commented on the stock. Argus upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $80.00 price objective on the stock in a report on Monday, August 18th. Mizuho set a $75.00 price target on shares of Hologic in a research report on Thursday, July 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research report on Tuesday, May 27th. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Finally, Stephens lowered their price objective on shares of Hologic from $77.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Hologic Stock Up 1.6%

HOLX stock opened at $68.26 on Friday. The stock has a market capitalization of $15.18 billion, a P/E ratio of 28.32, a PEG ratio of 2.44 and a beta of 0.49. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic has a one year low of $51.90 and a one year high of $84.39. The company has a 50 day moving average price of $65.90 and a two-hundred day moving average price of $62.49.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the previous year, the company earned $1.06 EPS. Hologic’s revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, sell-side analysts expect that Hologic will post 4.28 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HOLX. CYBER HORNET ETFs LLC bought a new stake in Hologic in the 2nd quarter valued at about $40,000. Headlands Technologies LLC lifted its stake in Hologic by 2.6% in the second quarter. Headlands Technologies LLC now owns 40,380 shares of the medical equipment provider’s stock worth $2,631,000 after acquiring an additional 1,036 shares during the period. CANADA LIFE ASSURANCE Co grew its position in shares of Hologic by 23.1% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 351,042 shares of the medical equipment provider’s stock worth $22,903,000 after buying an additional 65,848 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Hologic by 40.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,048 shares of the medical equipment provider’s stock valued at $264,000 after acquiring an additional 1,157 shares in the last quarter. Finally, MUFG Securities EMEA plc bought a new stake in Hologic in the 2nd quarter worth about $43,000. Institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.